Molecular Testing of Lung Cancers.

Area of Science:

• Oncology
• Molecular Pathology
• Genetics

Background:

• Targeted therapies are standard for lung cancer, guided by molecular diagnostics.
• Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are key predictive biomarkers.
• The landscape of druggable genetic alterations in lung cancer is expanding.

Purpose of the Study:

• To propose expanded guidelines for molecular testing of lung cancers.
• To categorize molecular biomarkers into mutations, gene rearrangements, and amplifications.
• To aid pathologists in identifying patients for precision therapeutics.

Main Methods:

• Review and categorization of known molecular biomarkers in lung cancer.
• Grouping biomarkers into mutations, gene rearrangements, and amplifications.
• Development of proposed guidelines for molecular testing strategies.

Main Results:

• Established three main categories for molecular biomarkers: mutations, gene rearrangements, and amplifications.
• Highlighted the growing list of actionable genetic alterations beyond EGFR and ALK.
• Emphasized the critical role of pathologists in sample management and timely molecular testing.

Conclusions:

• Updated molecular testing guidelines are essential for effective lung cancer precision medicine.
• Comprehensive molecular profiling is crucial for identifying patients eligible for targeted therapies.
• Pathologists play a vital role in the accurate and efficient delivery of precision oncology.